Treace Medical Concepts Inc
$ 2.10
2.94%
26 Feb - close price
- Market Cap 129,985,000 USD
- Current Price $ 2.10
- High / Low $ 2.10 / 1.94
- Stock P/E N/A
- Book Value 1.40
- EPS -0.80
- Next Earning Report 2026-02-27
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.15 %
- ROE -0.52 %
- 52 Week High 9.56
- 52 Week Low 1.81
About
Treace Medical Concepts, Inc., an orthopedic medical device company, is dedicated to the design, manufacture, and marketing of biological devices and / or solutions for foot and ankle surgeons in the United States. The company is headquartered in Ponte Vedra Beach, Florida.
Analyst Target Price
$4.20
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-26 | 2025-11-06 | 2025-08-07 | 2025-05-05 | 2025-02-25 | 2024-11-05 | 2024-08-06 | 2024-05-07 | 2024-02-27 | 2023-11-09 | 2023-08-08 | 2023-05-08 |
| Reported EPS | 0 | -0.26 | -0.28 | -0.2468 | -0.0016 | -0.25 | -0.29 | -0.3 | -0.1 | -0.28 | -0.2 | -0.23 |
| Estimated EPS | -0.1521 | -0.28 | -0.29 | -0.3022 | -0.0427 | -0.27 | -0.29 | -0.3 | -0.09 | -0.26 | -0.24 | -0.23 |
| Surprise | 0.1521 | 0.02 | 0.01 | 0.0554 | 0.0411 | 0.02 | 0 | 0 | -0.01 | -0.02 | 0.04 | 0 |
| Surprise Percentage | 100% | 7.1429% | 3.4483% | 18.3322% | 96.2529% | 7.4074% | 0% | 0% | -11.1111% | -7.6923% | 16.6667% | 0% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-27 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.15 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TMCI
2026-02-25 13:52:55
Treace Medical Concepts Inc (TMCI) is anticipated to report a loss of 15 cents per share, according to this earnings preview. This information is provided by Refinitiv and Reuters, highlighting expectations for the company's upcoming financial disclosure.
2026-02-24 11:52:28
Treace Medical Concepts, Inc. will showcase new product innovations and present updated clinical study data at the 2026 ACFAS Annual Scientific Conference. Key highlights include the commercialization of SpeedTMT™ Rapid Compression Implant and the Lapiplasty® Lightning™ System, alongside presentations on the ALIGN3D™, MTA3D™, and SpeedMTP® clinical studies, demonstrating positive outcomes for early weight-bearing and deformity correction. These advancements aim to strengthen Treace’s leadership in the surgical treatment of bunions and related midfoot deformities.
2026-02-24 06:52:55
Wall Street Zen upgraded Treace Medical Concepts (NASDAQ:TMCI) from "sell" to "hold," although the general analyst consensus remains "Reduce" with an average price target of $4.21. The company's shares are trading near their 12-month low, reflecting recent weakness. Treace Medical Concepts specializes in surgical solutions for foot and ankle conditions, with its Lapiplasty 3D Bunion Correction System as its flagship product.
2026-02-22 02:58:03
Treace Medical Concepts, Inc. and Fusion Orthopedics, LLC have announced an amicable resolution to their litigation. The lawsuit, filed by Treace Medical, involved allegations of patent, trademark, and copyright infringement, along with unfair trade practices concerning their bunion surgery products. Fusion Orthopedics had filed counterclaims including false advertising, but both parties have now settled the matter under confidential terms.
2026-02-19 17:19:03
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Treace Medical Concepts, Inc. (TMCI) following potential corporate wrongdoing. The firm is encouraging investors who purchased Treace Medical securities before May 8, 2023, and still hold them, to join the investigation. The firm operates on a contingency fee basis, aiming to recover investor capital and ensure corporate accountability.
2026-02-17 07:57:32
Treace Medical Concepts, Inc. (NASDAQ:TMCI) has received an average "Reduce" rating from six brokerages, with two recommending "sell" and four "hold", and a consensus one-year price target of $4.21. Institutional ownership is high at 84.08%, with significant recent activity from hedge funds like AQR Capital Management and Millennium Management. The stock is currently under pressure, trading at its 12-month low of $1.86 and below its 200-day simple moving average.
